Health Care [ 4/12 ] | Biotechnology [ 13/75 ]
NASDAQ | Common Stock
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 26 | -0.02 Increased by +40.45% | -0.03 Increased by +24.29% |
| Nov 5, 25 | -0.03 Increased by +25.00% | -0.03 |
| Aug 6, 25 | -0.02 Increased by +80.00% | -0.03 Increased by +33.33% |
| Apr 30, 25 | -0.03 Increased by +66.67% | -0.04 Increased by +15.97% |
| Feb 26, 25 | -0.04 Increased by +60.44% | -0.05 Increased by +23.28% |
| Nov 7, 24 | -0.04 Increased by +50.00% | -0.08 Increased by +50.00% |
| Aug 8, 24 | -0.10 Decreased by -11.11% | -0.10 |
| May 2, 24 | -0.09 Decreased by -28.57% | -0.10 Increased by +10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 48.02 M Increased by +1.01% | -31.14 M Decreased by -22.85% | Decreased by -64.86% Decreased by -21.62% |
| Sep 30, 25 | 47.23 M Increased by +67.05% | -18.43 M Increased by +30.32% | Decreased by -39.02% Increased by +58.29% |
| Jun 30, 25 | 49.04 M Increased by +5.46 K% | -16.38 M Increased by +75.70% | Decreased by -33.39% Increased by +99.56% |
| Mar 31, 25 | 39.60 M Increased by +12.93 K% | -19.84 M Increased by +64.19% | Decreased by -50.08% Increased by +99.73% |
| Dec 31, 24 | 47.54 M Increased by +206.58 K% | -25.35 M Increased by +51.22% | Decreased by -53.33% Increased by +99.98% |
| Sep 30, 24 | 28.27 M Increased by +17.14 K% | -26.45 M Increased by +40.97% | Decreased by -93.55% Increased by +99.66% |
| Jun 30, 24 | 882.00 K Increased by +2.94 K% | -67.38 M Decreased by -36.88% | Decreased by -7.64 K% Increased by +95.50% |
| Mar 31, 24 | 304.00 K Increased by +1.35 K% | -55.39 M Decreased by -45.30% | Decreased by -18.22 K% Increased by +89.96% |